Immune biomarkers associated with clinical benefit from atezolizumab (MPDL3280a; anti-PD-L1) in advanced urothelial bladder cancer (UBC). Issue 2 (December 2015) - Powles, Thomas; Nickles, Dorothee; Van Allen, Eliezer; Chappey, Colombe; Zou, Wei; Kowanetz, Marcin; Kadel, Edward; Denker, Mitchell; Boyd, Zachary; Vogelzang, Nicholas; Kim, Joseph; Bellmunt, Joaquim; et al.